Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.
2.

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.

J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11.

3.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
5.

Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.

Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E.

J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131.

PMID:
23247908
6.

Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.

Gosai P, Ducharme MP, Godfrey AR, Freeman JC, Monif T, Kumar KS, Kumar S, Mudnaik R, Katikaneni P.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):895-907. doi: 10.5414/CP201764.

PMID:
23673291
7.

Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.

Devarakonda K, Morton T, Margulis R, Giuliani M, Barrett T.

Drug Des Devel Ther. 2014 Aug 19;8:1125-34. doi: 10.2147/DDDT.S64261. eCollection 2014.

8.

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Sellers EM, Perrino PJ, Colucci SV, Harris SC.

J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.

PMID:
23784739
9.
10.
12.

Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.

Kopecky EA, Fleming AB, Noonan PK, Varanasi RK, Grima M, Saim S, Mayock SP.

J Opioid Manag. 2014 Jul-Aug;10(4):233-46. doi: 10.5055/jom.2014.0211.

PMID:
25162603
13.
14.
15.

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.

Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P.

J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2.

PMID:
26011742
17.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
18.

Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.

Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ.

Pain Med. 2012 Jun;13(6):790-801. doi: 10.1111/j.1526-4637.2012.01380.x. Epub 2012 May 8.

PMID:
22568663
19.

Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.

Eisenhauer TD, Matchett M, Heasley R, Morton T, Devarakonda K, Giuliani M, Young JL, Barrett T.

Drug Dev Ind Pharm. 2016 Jan;42(1):157-165. Epub 2015 Jul 6.

PMID:
26146769
20.

Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.

Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M.

Clin Ther. 2015 Feb 1;37(2):390-401. doi: 10.1016/j.clinthera.2014.11.014. Epub 2014 Dec 24.

PMID:
25542074

Supplemental Content

Support Center